aTyr Pharma's Phase 3 Success Boosts Market Confidence

San Diego, Monday, 15 September 2025.
aTyr Pharma reports significant Phase 3 trial success for efzofitimod in treating pulmonary sarcoidosis, causing a 7.5% stock surge and positioning the company as a potential industry leader.